SHC
Sotera HealthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-05
Current thesis
Sotera executes on cost‑savings and margin initiatives, European pricing stabilizes, and secondary float pressure subsides — enabling ~50%+ upside from current levels as organic growth and higher utilization drive EBITDA expansion.
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-08-06 · BMO.
What can break
2026 debt maturities and refinancing risk
Momentum
77
Value
63
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.64 · Bull $26.46 · Bear $12.35
Earnings
2026-08-06 · BMO
Data freshness
Prices
As of 2026-08-05
Fundamentals
As of 2026-08-05 • Vendor: Data Vendor v1
Scores
As of 2026-08-05 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-01 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-08-05
Investment thesis
As of 2026-08-05
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $20.44
Why
Momentum77 · Δ7d +18.1
Value63 · Δ7d +0.1
Sentiment60 · Δ7d +12.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
77
10% active weight
Current posture
7d trendImproving
Δ7d
+18.1
Δ21d
-3.2
Value
63
40% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
60
49% active weight
Current posture
7d trendImproving
Δ7d
+12.5
Δ21d
+8.1
Why this grade
Composite grade B. Momentum 76.5 / Value 63.2 / Sentiment 60.2
Fundamentals (TTM)As of 2026-08-05
Fundamentals (TTM)
As of 2026-08-05
Market Cap
$5.13B
Beta
1.82
Shares Out
285.17M
P/E (TTM)
94.8
P/S (TTM)
4.52
P/FCF (TTM)
60.02
Rev YoY
+10.0%
EPS YoY
-297.4%
Gross Margin
+53.7%
Op Margin
+24.1%
Net Debt
$1.93B
Current Ratio
2.82
As of 2026-08-05 • Updated nightlySource: Internal modelMethodology